Search This Blog

Wednesday, October 12, 2022

Opioids Most Common Contributor to Fatal Poisonings in Young Kids

 Opioids were the most common contributor to fatal poisonings among children ages 5 and younger in the U.S., according to an analysis of data from 40 states.

In this age group, the proportion of opioids accounting for fatal poisonings increased from 24% in 2005 to 52% in 2018, reported Christopher Gaw, MD, MBE, of the Children's Hospital of Philadelphia, during the American Academy of Pediatrics annual meeting.

"We're assuming that illicit substances such as fentanyl are driving the increasing proportion of [opioid-related] pediatric fatalities that we're seeing," Gaw told MedPage Today.

Illicit and prescription opioids contributed to 42% of all fatal poisonings tracked from 2005-2018, followed by over-the-counter drugs such as painkillers and cold/allergy medications (13%), other/unspecified illicit drugs (13%), other/unspecified over-the-counter or prescription drugs (9%), and other substances/toxins (6%). Carbon monoxide poisoning contributed to 6% of deaths.

Which opioids are contributing the most? The data don't say. "There's a lot of interest in illicit fentanyl in the past couple of years, and it is likely a contributor to the increasing proportion of deaths described in our study," Gaw noted. "But we can't confirm that concretely with the data."

Opioid poisonings are often accidental, he said. "There's maybe an opioid pill on the ground or under the couch, and a lot of the children in this age range are in the oral exploratory stage," he added. "Children weigh much less than adults, so that one pill just gets amplified."

In other cases, children may chew on opioid pain patches or ingest opioids in powder form, he said.

Naloxone (Narcan) is the typical treatment for opioid overdoses in children and adults, he noted. "It's the antidote for severe or life-threatening opioid poisonings for any age."

While other studies have tracked a rise in fatal opioid poisonings in children, this study is notable because it focuses on the youngest children and reviews data from the National Fatality Review-Case Reporting System. Child death review committees examine autopsy reports and medical records to "try to review as many deaths as feasible," Gaw said, although they may miss some in their jurisdictions.

Due to the limitations of their data, the researchers didn't release the total number of poisoning deaths per year. An increase in cases "could simply mean child death reviews were able to review more deaths in a given year or over time" due to factors like funding or participation, Gaw explained. As a result, it's not possible to know whether the rise in opioid-related poisonings have boosted the overall number of deaths.

Of 731 fatal pediatric poisoning cases from 2005-2018, 53% were in boys, 40% were white, 30% were Black, and 16% were Hispanic; 61% occurred at home, and 15% had a history of maltreatment.


Disclosures

Mirati, Aadi Partner to Evaluate Therapies for Lung Cancer and Other Solid Tumors

  Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company, and Aadi Bioscience, Inc (Nasdaq: AADI), a commercial stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced a clinical collaboration to evaluate the combination of adagrasib, a KRASG12C selective inhibitor, and nab-sirolimus, a small molecule mTOR inhibitor complexed with human albumin in KRAS G12C mutant non-small cell lung cancer (NSCLC) and other solid tumors.

The primary objective of this multi-center, single-arm, open-label Phase 1/2 trial is to determine the optimal dose and recommended Phase 2 dose for the combination of adagrasib and nab-sirolimus in patients with KRASG12C - mutant solid tumors. In addition, the study will investigate the safety, tolerability and efficacy of adagrasib and nab-sirolimus in combination in patients both with and without prior exposure to a KRASG12C inhibitor. The trial will build on preclinical data showing enhanced anti-tumor efficacy with the combination of adagrasib and nab-sirolimus relative to either agent alone.

https://www.biospace.com/article/releases/mirati-therapeutics-and-aadi-bioscience-partner-to-evaluate-the-combination-of-adagrasib-with-nab-sirolimus-in-patients-with-advanced-non-small-cell-lung-cancer-and-other-solid-tumors-with-a-kras-g12c-mutation/

Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma Giants

 

  • Emergex Vaccines Holding Limited acquired the assets of Zosano Pharma Corporation. The sale was part of the customary proceedings after Zosano filed for bankruptcy in June.
  • The assets acquired include intellectual property, license agreements, and manufacturing equipment. 
  • They also include Zosano's proprietary microneedle array patch (MAP) intradermal drug delivery system, including a reusable applicator, solid-coated microneedle array patch technology, product packaging, methods for formulation and microneedle coating, and specialized equipment.
  • Emergex has previously completed proof-of-concept studies, coating Zosano's MAP technology-based microneedle patches with Emergex vaccine candidates, and observed favorable shelf-life characteristics. 
  • In May, Zosano suspended its M207 program to preserve its capital and cash resources
  • Additionally, the company's remaining feasibility study with a pharmaceutical partner is expected to conclude this quarter.
  • Novo Nordisk A/S  once paid $1 million upfront to use Zosano's patch system to develop transdermal versions of select Novo glucagon-like peptide-1 (GLP-1) analogs. In 2015 the companies terminated the pact.
  • Eli Lilly And Co  once teamed up with Zosano and invested $15 million to commercialize a treatment for osteoporosis, but the companies later dissolved the pact.